Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder

Psychoneuroendocrinology

Volumn 52, Issue 1, 2015, Pages 200-211

  Savitz, Jonathan ^a,b   Dantzer, Robert ^c   Wurfel, Brent E ^a   Victor, Teresa A ^a   Ford, Bart N ^a   Bodurka, Jerzy ^a,d   Bellgowan, P S F ^a,b   Teague, T Kent ^e,f,g   Drevets, Wayne C ^h  

^a LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^b UNIVERSITY OF TULSA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e University of Oklahoma Tulsa College of Medicine   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^g OKLAHOMA STATE UNIVERSITY   (United States)

^h JOHNSON AND JOHNSON   (United States)

Author keywords

Bipolar disorder; Hippocampus; Inflammation; Kynurenine; Magnetic resonance imaging; Quinolinic acid

Indexed keywords

3 HYDROXYKYNURENINE; KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID; 3-HYDROXYKYNURENINE;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; BODY MASS; BRAIN LEVEL; BRAIN SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DSM-IV-TR; FEMALE; GRAY MATTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; TANDEM MASS SPECTROMETRY; AMYGDALA; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AMYGDALA; BIPOLAR DISORDER; FEMALE; HIPPOCAMPUS; HUMANS; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; QUINOLINIC ACID;

EID: 84922610676     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.11.015     Document Type: Article

References (48)

1. Amaral M., Levy C., Heyes D.J., Lafite P., Outeiro T.F., Giorgini F., Leys D., Scrutton N.S. Structural basis of kynurenine 3-monooxygenase inhibition. Nature 2013, 496:382-385.
2. Bellac C.L., Coimbra R.S., Christen S., Leib S.L. Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. Neurobiol. Dis. 2006, 24:395-402.
3. Birch P.J., Grossman C.J., Hayes A.G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 1988, 154:85-87.
4. Chiarugi A., Meli E., Moroni F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 2001, 77:1310-1318.
5. Cobb J.A., Simpson J., Mahajan G.J., Overholser J.C., Jurjus G.J., Dieter L., Herbst N., May W., Rajkowska G., Stockmeier C.A. Hippocampal volume and total cell numbers in major depressive disorder. J. Psychiatr. Res. 2013, 47:299-306.
6. Cutler J.A., Rush A.J., McMahon F.J., Laje G. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J. Psychopharmacol. 2012, 26:360-367.
7. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
8. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
9. Duric V., Banasr M., Stockmeier C.A., Simen A.A., Newton S.S., Overholser J.C., Jurjus G.J., Dieter L., Duman R.S. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int. J. Neuropsychopharmacol. 2013, 16:69-82. (official scientific journal of the Collegium Internationale Neuropsychopharmacologicum).
10. Haarman B.C., Riemersma-Van der Lek R.F., de Groot J.C., Ruhe H.G., Klein H.C., Zandstra T.E., Burger H., Schoevers R.A., de Vries E.F., Drexhage H.A., Nolen W.A., Doorduin J. Neuroinflammation in bipolar disorder-a [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav. Immun. 2014, 40:219-225.
11. Hodes G.E., Pfau M.L., Leboeuf M., Golden S.A., Christoffel D.J., Bregman D., Rebusi N., Heshmati M., Aleyasin H., Warren B.L., Lebonté B., Horn S., Lapidus K.A., Stelzhammer V., Wong E.H., Bahn S., Krishnan V., Bolaños-Guzman C.A., Murrough J.W., Merad M., Russo S.J. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc. Natl. Acad. Sci. U.S.A. 2014, 111(45):16136-16141.10.1073/pnas.1415191111.
12. Johansson A.S., Owe-Larsson B., Asp L., Kocki T., Adler M., Hetta J., Gardner R., Lundkvist G.B., Urbanska E.M., Karlsson H. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J. Psychiatr. Res. 2013, 47:1815-1823.
13. Kocki T., Wnuk S., Kloc R., Kocki J., Owe-Larsson B., Urbanska E.M. New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. J. Neural. Transm. 2012, 119:235-243.
14. Lavebratt C., Olsson S., Backlund L., Frisen L., Sellgren C., Priebe L., Nikamo P., Traskman-Bendz L., Cichon S., Vawter M.P., Osby U., Engberg G., Landen M., Erhardt S., Schalling M. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol. Psychiatry 2014, 19:334-341.
15. Leeds P.R., Yu F., Wang Z., Chiu C.T., Zhang Y., Leng Y., Linares G.R., Chuang D.M. A new avenue for lithium: intervention in traumatic brain injury. ACS Chem. Neurosci. 2014.
16. Maciejak P., Szyndler J., Turzynska D., Sobolewska A., Kolosowska K., Lehner M., Plaznik A. The kynurenine pathway: a missing piece in the puzzle of valproate action?. Neuroscience 2013, 234:135-145.
17. McEwen B.S. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 1999, 22:105-122.
18. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
19. Monnerie H., Shashidhara S., Le Roux P.D. Effect of excess extracellular glutamate on dendrite growth from cerebral cortical neurons at 3 days in vitro: involvement of NMDA receptors. J. Neurosci. Res. 2003, 74:688-700.
20. Moroni F., Carpenedo R., Cozzi A., Meli E., Chiarugi A., Pellegrini-Giampietro D.E. Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage. Adv. Exp. Med. Biol. 2003, 527:127-136.
21. Myint A.M., Kim Y.K., Verkerk R., Park S.H., Scharpe S., Steinbusch H.W., Leonard B.E. Tryptophan breakdown pathway in bipolar mania. J. Affect Disord. 2007, 102:65-72.
22. Myint A.M., Schwarz M.J., Verkerk R., Mueller H.H., Zach J., Scharpe S., Steinbusch H.W., Leonard B.E., Kim Y.K. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun. 2011, 25:1576-1581.
23. Nassar A., Azab A.N. Effects of lithium on inflammation. ACS Chem. Neurosci. 2014.
24. Ogawa T., Matson W.R., Beal M.F., Myers R.H., Bird E.D., Milbury P., Saso S. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992, 42:1702-1706.
25. Okuda S., Nishiyama N., Saito H., Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:12553-12558.
26. Olsson S.K., Samuelsson M., Saetre P., Lindstrom L., Jonsson E.G., Nordin C., Engberg G., Erhardt S., Landen M. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 2010, 35:195-199.
27. Olsson S.K., Sellgren C., Engberg G., Landen M., Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012, 14:719-726.
28. Petrik D., Lagace D.C., Eisch A.J. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building?. Neuropharmacology 2012, 62:21-34.
29. Phillips M.L., Swartz H.A. A critical appraisal of neuroimaging studies of bipolar bisorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am. J. Psychiatry 2014, 171(8):829-843.
30. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
31. Rejdak K., Bartosik-Psujek H., Dobosz B., Kocki T., Grieb P., Giovannoni G., Turski W.A., Stelmasiak Z. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett. 2002, 331:63-65.
32. Sapko M.T., Guidetti P., Yu P., Tagle D.A., Pellicciari R., Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Experimental neurology 2006, 197:31-40.
33. Savitz J., Drevets W.C. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci. Biobehav. Rev. 2009, 33:699-771.
34. Savitz J., Drevets W.C., Smith C.M., Victor T.A., Wurfel B.E., Bellgowan P.S., Bodurka J., Teague T.K., Dantzer R. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2014, (official publication of the American College of Neuropsychopharmacology).10.1038/npp.2014.194.
35. Savitz J., Nugent A.C., Bogers W., Liu A., Sills R., Luckenbaugh D.A., Bain E.E., Price J.L., Zarate C., Manji H.K., Cannon D.M., Marrett S., Charney D.S., Drevets W.C. Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. NeuroImage 2010, 49:2966-2976.
36. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13:465-477.
37. Schwarz M.J., Guillemin G.J., Teipel S.J., Buerger K., Hampel H. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:345-352.
38. Steiner J., Walter M., Gos T., Guillemin G.J., Bernstein H.G., Sarnyai Z., Mawrin C., Brisch R., Bielau H., Meyer zu Schwabedissen L., Bogerts B., Myint A.M. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J. Neuroinflammation 2011, 8:94.
39. Stockmeier C.A., Mahajan G.J., Konick L.C., Overholser J.C., Jurjus G.J., Meltzer H.Y., Uylings H.B., Friedman L., Rajkowska G. Cellular changes in the postmortem hippocampus in major depression. Biol. Psychiatry 2004, 56:640-650.
40. Stone T.W., Forrest C.M., Darlington L.G. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J. 2012, 279:1386-1397.
41. Stone T.W., Stoy N., Darlington L.G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci. 2013, 34:136-143.
42. Ting K.K., Brew B.J., Guillemin G.J. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J. Neuroinflammation 2009, 6:36.
43. Uher R., Tansey K.E., Dew T., Maier W., Mors O., Hauser J., Dernovsek M.Z., Henigsberg N., Souery D., Farmer A., McGuffin P. An inflammatory biomarker as a differential predictor of outcome of depression treatment with Escitalopram and Nortriptyline. Am. J. Psychiatry 2014,10.1176/appi.ajp.2014.14010094.
44. Vogelgesang S.A., Heyes M.P., West S.G., Salazar A.M., Sfikakis P.P., Lipnick R.N., Klipple G.L., Tsokos G.C. Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. J. Rheumatol. 1996, 23:850-855.
45. Webster M.J., O'Grady J., Kleinman J.E., Weickert C.S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005, 133:453-461.
46. Wu M.V., Shamy J.L., Bedi G., Choi C.W., Wall M.M., Arango V., Boldrini M., Foltin R.W., Hen R. Impact of social status and antidepressant treatment on neurogenesis in the baboon hippocampus. Neuropsychopharmacology 2014, 39:1861-1871. (official publication of the American College of Neuropsychopharmacology).
47. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., Thuret S., Price J., Pariante C.M. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949. (official publication of the American College of Neuropsychopharmacology).
48. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Guidetti P., Wu H.Q., Lee J., Truong J., Andrews-Zwilling Y., Hsieh E.W., Louie J.Y., Wu T., Scearce-Levie K., Patrick C., Adame A., Giorgini F., Moussaoui S., Laue G., Rassoulpour A., Flik G., Huang Y., Muchowski J.M., Masliah E., Schwarcz R., Muchowski P.J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.